Publication:
Native High-Density Lipoprotein and Melatonin Improve Platelet Response Induced by Glycated Lipoproteins

dc.contributor.authorsOzsavci, D.; Nazli, A.; Ozakpinar, O. Bingol; Demirel, G. Yanikkaya; Kural, B. Vanizor; Sener, A.
dc.date.accessioned2022-03-12T22:26:33Z
dc.date.accessioned2026-01-10T17:12:21Z
dc.date.available2022-03-12T22:26:33Z
dc.date.issued2018
dc.description.abstractActivated platelets and glycated lipoproteins are responsible for atherothrombosis in diabetics. Melatonin and native high-density lipoproteins are crucial in the preservation of pro/oxidant-antioxidant balance. The aim of the present study was to investigate the in vitro effects of native high-density lipoproteins and melatonin on altering the platelet response induced by glycated lipoproteins. Low-density lipoproteins and high-density lipoproteins were purified from plasma by ultracentrifugation and were glycated with glucose for three weeks. After incubation with or without melatonin/or native high-density lipoproteins, low-density lipoproteins, glycated low-density lipoproteins/glycated high-density lipoproteins were added to ADP-induced platelets. Oxidative parameters, caspase-3/9 and nitric oxide levels were measured spectrophotometrically; CD62-P/annexin-V expression was determined by flow cytometry. In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, platelet malondialdehyde/protein carbonyl, P-selectin, annexin-V, caspase-3/9 levels were increased (ranging from P < 0.001 to P < 0.01); glutathione and nitric oxide levels were reduced (ranging from P < 0.001 to P < 0.01). In glycated low-density lip oprotein/glycated high-density lipoprotein-treated groups, melatonin treatment reduced malondialdehyde, protein carbonyl, CD62-P, annexin-V and caspase-3/9 (P < 0.001, P < 0.01) levels and elevated nitric oxide (only glycated low-density lipoproteins). In glycated low-density lipoprotein/glycated high-density lipoprotein-treated groups, native high-density lipoprotein treatment reduced malondialdehyde, protein carbonyl, annexin-V, caspase-3/9 levels (P < 0.001, P < 0.01) and increased glutathione; nitric oxide levels (only with gly-HDL). Both melatonin and high-density lipoproteins should be regarded as novel promising mechanism-based potential therapeutic targets to prevent atherothrombosis in diabetics.
dc.identifier.doidoiWOS:000470081800004
dc.identifier.issn0015-5500
dc.identifier.pubmed30724160
dc.identifier.urihttps://hdl.handle.net/11424/235082
dc.identifier.wosWOS:000470081800004
dc.language.isoeng
dc.publisherCHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE
dc.relation.ispartofFOLIA BIOLOGICA
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjecthigh-density lipoproteins
dc.subjectin vitro glycation
dc.subjectlow-density lipoproteins
dc.subjectmelatonin
dc.subjectplatelets
dc.subjectOXIDATIVE STRESS
dc.subjectEND-PRODUCTS
dc.subjectAPOPTOSIS
dc.subjectEXPRESSION
dc.subjectCELLS
dc.subjectLDL
dc.subjectHDL
dc.subjectPROLIFERATION
dc.subjectCHOLESTEROL
dc.subjectDYSFUNCTION
dc.titleNative High-Density Lipoprotein and Melatonin Improve Platelet Response Induced by Glycated Lipoproteins
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage152
oaire.citation.issue4
oaire.citation.startPage144
oaire.citation.titleFOLIA BIOLOGICA
oaire.citation.volume64

Files